Page last updated: 2024-11-05
thalidomide and Epithelial Ovarian Cancer
thalidomide has been researched along with Epithelial Ovarian Cancer in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Research Excerpts
Excerpt | Relevance | Reference |
"Lenalidomide has dual antiangiogenic and immunomodulatory properties and confirmed antitumor activity in hematologic malignancies." | 2.79 | A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma. ( Berton-Rigaud, D; Fabbro, M; Favier, L; Lesoin, A; Lortholary, A; Mari, V; Pujade-Lauraine, E; Ray-Coquard, I; Selle, F; Sevin, E, 2014) |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
Selle, F | 1 |
Sevin, E | 1 |
Ray-Coquard, I | 1 |
Mari, V | 1 |
Berton-Rigaud, D | 1 |
Favier, L | 1 |
Fabbro, M | 1 |
Lesoin, A | 1 |
Lortholary, A | 1 |
Pujade-Lauraine, E | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status |
A Two Stage Trial of lénalidomide (Revlimid®) : a Phase II Study of lénalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of lénalidomide in Combination With Carboplatin and Lipo[NCT01111903] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2009-05-31 | Completed |
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trials
1 trial available for thalidomide and Epithelial Ovarian Cancer